Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer

Drug Discovery Today: Therapeutic Strategies

Volumn 7, Issue 1-2, 2010, Pages 31-35

  Aragon Ching, Jeanny B ^a   Dahut, William L ^b  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE ACETATE; AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTOCHROME P450 17; CYTOCHROME P450 INHIBITOR; DOCETAXEL; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; KETOCONAZOLE; ORTERONEL; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE; UNCLASSIFIED DRUG; VN 124 1;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CORTICOSTEROID THERAPY; ENZYME INHIBITION; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; LOW DRUG DOSE; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

EID: 80054991821     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2011.02.004     Document Type: Review

References (40)

1. Jemal, A. et al. (2010) Cancer Statistics, 2010. CA Cancer J. Clin., Epub ahead of print
2. Pound, C.R. et al. (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597 (Pubitemid 29211767)
3. Huggins, C. and Bergenstal, D.M. (1952) Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12, 134-141
4. Debes, J.D. and Tindall, D.J. (2004) Mechanisms of androgen-refractory prostate cancer. N. Engl. J. Med. 351, 1488-1490 (Pubitemid 39315314)
5. Tannock, I.F. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (Pubitemid 39315317)
6. Kantoff, P.W. et al. (2010) Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N. Engl. J. Med. 363, 411-422
7. Prostate Cancer Trialists' Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346, 265-269
8. Bubley, G.J. et al. (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 17, 3461-3467 (Pubitemid 29517916)
9. Page, S.T. et al. (2006) Persistent intraprostatic androgen concentrations after medical castration in healthy men. J. Clin. Endocrinol. Metab. 91, 3850-3856 (Pubitemid 44536854)
10. Mostaghel, E.A. et al. (2007) Intraprostatic androgens and androgenregulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67, 5033-5041 (Pubitemid 46910214)
11. Chen, C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39 (Pubitemid 38524696)
12. Rubin, M.A. (2008) Targeted therapy of cancer: new roles for pathologists - prostate cancer. Mod Pathol. 21 (Suppl. 2), S44-55 (Pubitemid 351592771)
13. Grossmann, M.E. et al. (2001) Androgen receptor signaling in androgenrefractory prostate cancer. J. Natl. Cancer Inst. 93, 1687-1697 (Pubitemid 33130257)
14. Hellerstedt, B.A. and Pienta, K.J. (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J. Clin. 52, 154-179 (Pubitemid 34546107)
15. Dupont, A. et al. (1993) Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol. 150, 908-913 (Pubitemid 23241297)
16. Kelly, W.K. and Scher, H.I. (1993) Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J. Urol. 149, 607-609 (Pubitemid 23094069)
17. Small, E.J. and Carroll, P.R. (1994) Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 43, 408-410 (Pubitemid 24111446)
18. Moul, J.W. et al. (1995) Molecular implications of the antiandrogen withdrawal syndrome. Semin. Urol. 13, 157-163
19. Taplin, M.E. (2007) Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 4, 236-244
20. Veldscholte, J. et al. (1990) A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 173, 534-540
21. Taplin, M.E. et al. (1999) Selection for androgen receptor mutations in prostatecancers treated withandrogenantagonist. CancerRes.59, 2511-2515
22. Small, E.J. et al. (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025-1033 (Pubitemid 41095034)
23. Trachtenberg, J. and Pont, A. (1984) Ketoconazole therapy for advanced prostate cancer. Lancet 2, 433-435 (Pubitemid 14059393)
24. Sikka, S.C. et al. (1985) In vitro inhibition of testosterone biosynthesis by ketoconazole. Endocrinology 116, 1920-1925 (Pubitemid 15067769)
25. Reid, A.H. et al. (2008) CYP17 inhibition as a hormonal strategy for prostate cancer. Nat. Clin. Pract. Urol. 5, 610-620
26. Attard, G. et al. (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 96, 1241-1246 (Pubitemid 41743917)
27. Barrie, S.E. et al. (1994) Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J. Steroid Biochem. Mol. Biol. 50, 267-273 (Pubitemid 24309119)
28. Attard, G. et al. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-4940
29. O'Donnell, A. et al. (2004) Hormonal impact of the 17alpha-hydroxylase/ C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317-2325 (Pubitemid 38961894)
30. Reid, A.H. et al. (2010) Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489-1495
31. Attard, G. et al. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571
32. Attard, G. et al. (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748
33. Ryan, C.J. et al. (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481-1488
34. Danila, D.C. et al. (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castrationresistant prostate cancer. J. Clin. Oncol. 28, 1496-1501
35. De Bono, J.S. et al. (2010) Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients with metastatic castration resistant prostate cancer (MCRPC) who have progressed after docetaxelbased chemotherapy: results of COU-AA-301, A Randomized Double-blind Placebo-controlled Phase III Study. Ann. Oncol. 21 (Suppl. 8), LBA5
36. Vasaitis, T. et al. (2008) Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3betahydroxy- 17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol. Cancer Ther. 7, 2348-2357
37. Handratta, V.D. et al. (2005) Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972-2984 (Pubitemid 40552912)
38. Dreicer, R. et al. (2010) Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J. Clin. Oncol. 28 (15-suppl.), Abstract 3084
39. Tran, C. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787-790
40. Scher, H.I. et al. (2010) Antitumour activity of MDV3100 in castrationresistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446.